Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Video

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Related Videos
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Jennifer Brown, MD, PhD
Saad J. Kenderian, MB, CHB
Eduardo Sotomayor, MD
Saad J. Kenderian, MB, CHB
Jennifer Brown, MD, PhD
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Ira Zackon, MD

BTK Inhibitor Selection for CLL/SLL Is Evolving in Community Settings

April 15th 2024
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
Simon Blanc, MD

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

April 12th 2024
Article
Saad J. Kenderian, MB, CHB, consultant in the Division of Hematology, Department of Internal Medicine, Department of Immunology, and Department of Molecular Medicine at the Mayo Clinic in Rochester, Minnesota

A Groundbreaking First in CLL/SLL: Liso-Cel Makes its Mark as Only CAR T-Cell Therapy Approved

March 25th 2024
Article